G
George Spencer-Green
Researcher at University of Cincinnati
Publications - 15
Citations - 3643
George Spencer-Green is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Rheumatology & Etanercept. The author has an hindex of 12, co-authored 15 publications receiving 3560 citations.
Papers
More filters
Journal ArticleDOI
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Ferdinand C. Breedveld,Michael H. Weisman,Arthur Kavanaugh,Stanley Cohen,Karel Pavelka,Ronald F van Vollenhoven,John T. Sharp,John L. Perez,George Spencer-Green +8 more
TL;DR: Combination therapy with adalimumab plus MTX was significantly superior to either MTX alone or ad alimumab alone in improving signs and symptoms of disease, inhibiting radiographic progression, and effecting clinical remission in patients with early, aggressive rheumatoid arthritis.
Journal ArticleDOI
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Mark C. Genovese,Joan M. Bathon,Richard J. Martin,Roy Fleischmann,John Tesser,Michael Schiff,Edward C. Keystone,Mary Chester M. Wasko,Larry W. Moreland,Arthur L. Weaver,Joseph A. Markenson,Grant W. Cannon,George Spencer-Green,Barbara K. Finck +13 more
TL;DR: Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.
Journal ArticleDOI
A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis.
Ellen M. Ginzler,Ellen M. Ginzler,Herbert S. Diamond,Max Weiner,Michael Schlesinger,James F. Fries,Cody Wasner,Thomas A. Medsger,Gayle Ziegler,John H. Klippel,Nortin M. Hadler,Daniel A. Albert,Evelyn V. Hess,George Spencer-Green,Arthur I. Grayzel,David Worth,Bevra H. Hahn,Eugene V. Barnett +17 more
TL;DR: A retrospective study of factors influencing survival in 1,103 patients with systemic lupus erythematosus was carried out at 9 university centers diverse in geographic, socioeconomic, and racial characteristics.
Journal ArticleDOI
A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death
Steven Rosner,Ellen M. Ginzler,Ellen M. Ginzler,Herbert S. Diamond,Max Weiner,Michael Schlesinger,James F. Fries,Cody Wasner,Thomas A. Medsger,Gayle Ziegler,John H. Klippel,Nortin M. Hadler,Daniel A. Albert,Evelyn V. Hess,George Spencer-Green,Arthur I. Grayzel,David Worth,Bevra H. Hahn,Eugene V. Barnett +18 more
TL;DR: Causes of death were examined for 1,103 systemic lupus erythematosus patients who were followed from 1965 to 1978 at 9 centers that participated in the Lupus Survival Study Group.
Journal Article
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results.
Roy Fleischmann,Scott Baumgartner,Elizabeth A. Tindall,Arthur L. Weaver,Larry W. Moreland,Michael Schiff,Richard J. Martin,George Spencer-Green +7 more
TL;DR: Etanercept is a new treatment option for older patients with RA and has substantial benefit and comparable safety regardless of patient age, and was well tolerated.